Anthropic's IPO, Platner's Campaign Controversies, and Blue Origin's Setback

June 2, 2026

58 min episode · 2 min read

Episode

58 min

Read time

2 min

Topics

Fundraising & VC, Artificial Intelligence

AI-Generated Summary

Published Jun 2, 2026

Key Takeaways

✓Anthropic's valuation speed: Anthropic reached a $965B valuation in five years — half the time OpenAI needed to hit $730B. The key strategic move was targeting enterprise customers rather than consumers. Google took 20 years to reach $1T. This speed represents what Galloway calls "financial teleportation," not normal capital formation.
✓AI investment risk concentration: 93% of US GDP growth currently derives from AI capital expenditure, creating dangerous market concentration. An MIT study shows 95% of CFOs report no measurable ROI on AI investments. When one major company announces spending cuts, the resulting market correction could trigger a recession equivalent to losing Germany's entire GDP.
✓Podcast acquisition dynamics: Podcast ad CPMs average $45 versus $13 for CNN, making the medium highly attractive to acquirers. RSS feed subscribers create durable moats that new entrants cannot replicate quickly. Top-ranked podcasts are almost always long-established shows, meaning scale commands 10x revenue multiples — a show with 10M monthly downloads is worth 4x one with 5M.
✓Crisis communications failure pattern: The Plattner campaign kept a damaging story alive by denying accurate reporting and attacking media outlets rather than owning the mistakes. The correct response framework: acknowledge specific failures, contextualize them within a broader record of service, and redirect to policy. Denial of corroborated facts extends news cycles indefinitely.
✓GLP-1 drugs vs. AI as investment thesis: Eli Lilly, headquartered in Indianapolis, became the first pharmaceutical company to breach a $1T market cap by betting early on GLP-1 drugs. Monthly costs dropped from $1,000 to $250–$500 within 12 months, demonstrating strong price elasticity. Galloway argues going long GLP-1 and short AI is the stronger decade-long investment position.

What It Covers

Kara Swisher and Scott Galloway cover Anthropic's confidential IPO filing after surpassing OpenAI's $730B valuation to reach $965B in five years, Maine Senate candidate Graham Plattner's sexting controversy, Blue Origin's New Glenn rocket explosion on the launch pad, and the podcasting acquisition market.

Key Questions Answered

•Anthropic's valuation speed: Anthropic reached a $965B valuation in five years — half the time OpenAI needed to hit $730B. The key strategic move was targeting enterprise customers rather than consumers. Google took 20 years to reach $1T. This speed represents what Galloway calls "financial teleportation," not normal capital formation.
•AI investment risk concentration: 93% of US GDP growth currently derives from AI capital expenditure, creating dangerous market concentration. An MIT study shows 95% of CFOs report no measurable ROI on AI investments. When one major company announces spending cuts, the resulting market correction could trigger a recession equivalent to losing Germany's entire GDP.
•Podcast acquisition dynamics: Podcast ad CPMs average $45 versus $13 for CNN, making the medium highly attractive to acquirers. RSS feed subscribers create durable moats that new entrants cannot replicate quickly. Top-ranked podcasts are almost always long-established shows, meaning scale commands 10x revenue multiples — a show with 10M monthly downloads is worth 4x one with 5M.
•Crisis communications failure pattern: The Plattner campaign kept a damaging story alive by denying accurate reporting and attacking media outlets rather than owning the mistakes. The correct response framework: acknowledge specific failures, contextualize them within a broader record of service, and redirect to policy. Denial of corroborated facts extends news cycles indefinitely.
•GLP-1 drugs vs. AI as investment thesis: Eli Lilly, headquartered in Indianapolis, became the first pharmaceutical company to breach a $1T market cap by betting early on GLP-1 drugs. Monthly costs dropped from $1,000 to $250–$500 within 12 months, demonstrating strong price elasticity. Galloway argues going long GLP-1 and short AI is the stronger decade-long investment position.

Notable Moment

Galloway argued that Blue Origin's launch pad explosion — estimated at roughly $1B in damage — is structurally necessary for innovation. Private space companies outpace NASA precisely because they can absorb launch pad failures that would be politically catastrophic for a government agency, making destruction a feature of the model.

Know someone who'd find this useful?